The Market for Drug Eluting Coronary Stents grew by 3% in 2008 reaching $4.2 billion globally. Decline in average selling price was offset by growth in procedure volume and improved penetration levels.
The US market remained stable at $1.8 billion accounting for 43% of the world market. The launch of Medtronic’s Endeavor zotarolimus-eluting stent and Abbott’s & Boston Scientific’s Xience and Promus everolimus-eluting stents during the year, redistributed market shares with JnJ’s Cypher losing the most.
The Market for Drug Eluting Coronary Stents is exhibiting clear evidence of recovery with average annual PCI volumes rising by 5% in the US and 4% in Europe. Average penetration rates are also rising in all markets.
Drug Eluting Coronary Stents Market – Current Situation & Future Outlook is a New 2009 Edition of our best selling report. The report offers a timely analysis of the latest happenings with market revenue and growth rates for main regions, up-to-date market shares for leading companies and brands and market forecasts to 2015.
With Drug Eluting Coronary Stents Market – Current Situation & Future Outlook, you’ll be able to:
-Understand current market dynamics, competitors positions and market shares. -Assess market size and growth potential for these combined drug devices. -Monitor the competition’s marketed and in-development products. -Identify emerging technologies and the companies behind them. -Assess market potential and have access to forecasts till 2015. -Leverage your own technology and brain storm new business opportunities. -Investigate mergers, acquisitions and licensing possibilities
Drug Eluting Coronary Stents Market – Current Situation & Future Outlook is targeted at busy senior executives in medical technology companies who are interested in developing an understanding of this highly dynamic market.
